Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)

Next Previous
X
Search
Trial Profile

Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary) ; Aluminium hydroxide/magnesium hydroxide
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Eosinophilia; Fibroma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Sarcoma; Scleroderma; Systemic mastocytosis
  • Focus Pharmacokinetics

    • Most Recent Events

    • 08 Apr 2009 Actual end date changed from Dec 2007 to Oct 2008 as reported by ClinicalTrials.gov.
    • 20 Dec 2007 Status changed from recruiting to completed.
    • 03 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top